Five‐year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra‐arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer

Abstract

Most treatment-related QOL issues deteriorate during treatment, improve in the first year, and then remain stable, except xerostomia, improving up to the 5-year assessment point. Survivors show more positive scores for fatigue, voice, and swallowing. QOL issues at 1 year, thus, for most already represent those after 5-year follow-up.